Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 3, 2012– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported consolidated financial results for the first quarter of 2012 and reviewed key first quarter accomplishments. “Since the achievement of the primary endpoint in our TIVO-1 study early in the first quarter, we’ve seen an increase in excitement in the medical oncology community for tivozanib

Download PDF Ficlatuzumab/Gefitinib Combination Was Well-Tolerated and Demonstrated Clinical Activity; Study Results Did Not Reach Statistical Significance Encouraging Signals of Anti-tumor Activity in Distinct Subpopulations CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 2, 2012– AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) announced today preliminary data from the exploratory, randomized Phase 2 study comparing the combination of ficlatuzumab and gefitinib, an EGFR tyrosine kinase

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 30, 2012– AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that the company’s management will present a company overview at upcoming investment conferences. Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8, 2012 at 3:30 p.m. (ET) at the InterContinental Hotel in Boston. David Johnston, chief financial officer, is scheduled

Download PDF CAMBRIDGE, Mass., Apr 26, 2012 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company’s first quarter ended March 31, 2012 will be released before the market opens on Thursday, May 3, 2012. The AVEO management team will host a conference call discussing the company’s financial results and

Download PDF Tivozanib Demonstrated Improved Median Progression-Free Survival Combined with a Well Tolerated Safety Profile in Patients with Advanced Renal Cell Carcinoma CAMBRIDGE, Mass., Apr 12, 2012 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported results from a successful Phase 2 clinical trial evaluating the efficacy and safety of tivozanib in 272 patients

Download PDF AVEO’s Novel, Internally-Discovered ErbB3 Inhibitory Antibody, AV-203, Entering Clinic This Year CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 27, 2012– AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that previously reported clinical data on tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and preclinical data on AV-203, AVEO’s ErbB3 inhibitory

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 27, 2012– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Cowen and Company 32nd Annual Health Care Conference on Monday, March 5, 2012 at 4:10 p.m. (EST) in Boston. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveopharma.com. A

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 14, 2012– AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today reported consolidated 2011 financial results and reviewed key progress achieved with its tivozanib and ficlatuzumab development programs in the fourth quarter of 2011. “The recent success of our Phase 3 registration trial of tivozanib in RCC, TIVO-1, marks an important milestone for AVEO as we